Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: The strong heart study

Journal of Clinical Hypertension

Volumn 14, Issue 1, 2012, Pages 13-19

  Barac, Ana ^a   Wang, Hong ^b,c   Shara, Nawar M ^b,c   de Simone, Giovanni ^d   Carter, Elizabeth A ^b,c   Umans, Jason G ^b,c   Best, Lyle G ^e   Yeh, Jeunliang ^f   Dixon, Damon B ^g   Devereux, Richard B ^h   Howard, Barbara V ^b,c   Panza, Julio A ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c Delaware   (United States)

^d FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^e MISSOURI BREAKS INDUSTRIES RESEARCH INC   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g Gila River Healthcare Corporation   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; MARKER;

ADULT; AGED; AMERICAN INDIAN; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; HAZARD RATIO; HEART FAILURE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS; FEMALE; FIBRINOGEN; HEALTH SURVEYS; HEART FAILURE; HUMANS; INDIANS, NORTH AMERICAN; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; UNITED STATES;

EID: 84855344076     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00560.x     Document Type: Article

References (24)

1. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428-1434.
2. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
3. Nagai T, Anzai T, Kaneko H, et al. C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension. 2011;57:208-215.
4. Schulz R, Heusch G. C-reactive protein: just a biomarker of inflammation or a pathophysiological player in myocardial function and morphology? Hypertension. 2011;57:151-153.
5. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
6. Bahrami H, Bluemke DA, Kronmal R, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;51:1775-1783.
7. Chinali M, de Simone G, Roman MJ, et al. Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the Strong Heart Study. J Am Coll Cardiol. 2008;52:932-938.
8. de Simone G, Devereux RB, Chinali M, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the strong heart study. J Hypertens. 2010;28:353-360.
9. Turkbey EB, McClelland RL, Kronmal RA, et al. The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc Imaging. 2010;3:266-274.
10. Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol. 2010;55:283-293.
11. Palmieri V, Celentano A, Roman MJ, et al. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J. 2003;145:467-474.
12. Palmieri V, Celentano A, Roman MJ, et al. Fibrinogen and preclinical echocardiographic target organ damage: the Strong Heart Study. Hypertension. 2001;38:1068-1074.
13. Tang WH, Katz R, Brennan ML, et al. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol. 2009;103:1269-1274.
14. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation. 1999;99:2389-2395.
15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-2752.
16. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-58.
17. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
18. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799-1809.
19. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55:2129-2137.
20. Suzuki T, Katz R, Jenny NS, et al. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the Cardiovascular Health study. Circ Heart Fail. 2008;1:242-248.
21. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005;112:1289-1295.
22. Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiol (Oxf). 2010;198:1-13.
23. Best LG, North KE, Li X, et al. Linkage study of fibrinogen levels: the Strong Heart Family study. BMC Med Genet. 2008;9:77.
24. Tang WH, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol. 2007;49:2364-2370.